Cargando…

Loss of MTSS1 results in increased metastatic potential in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlyin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeleniak, Ann E, Huang, Wei, Brinkman, Mary K, Fishel, Melissa L, Hill, Reginald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369978/
https://www.ncbi.nlm.nih.gov/pubmed/28146435
http://dx.doi.org/10.18632/oncotarget.14869
_version_ 1782518160774135808
author Zeleniak, Ann E
Huang, Wei
Brinkman, Mary K
Fishel, Melissa L
Hill, Reginald
author_facet Zeleniak, Ann E
Huang, Wei
Brinkman, Mary K
Fishel, Melissa L
Hill, Reginald
author_sort Zeleniak, Ann E
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlying mechanisms responsible for this progression have not been fully characterized. Here, we functionally test the role of metastasis suppressor 1 (MTSS1) in PDAC. Despite evidence showing that MTSS1 could be important for regulating metastasis in many different cancers, its function in PDAC has not been studied. Here, we show that loss of MTSS1 leads to increased invasion and migration in PDAC cell lines. Moreover, PDAC cells treated with cancer-associated fibroblast-conditioned media also have increased metastatic potential, which is augmented by loss of MTSS1. Finally, overexpression of MTSS1 in PDAC cell lines leads to a loss of migratory potential in vitro and an increase in overall survival in vivo. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion and migration driven by the tumor microenvironment and suggest that therapeutic strategies aimed at increasing MTSS1 levels may effectively slow the development of metastatic lesions, increasing survival of patients with PDAC.
format Online
Article
Text
id pubmed-5369978
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53699782017-04-17 Loss of MTSS1 results in increased metastatic potential in pancreatic cancer Zeleniak, Ann E Huang, Wei Brinkman, Mary K Fishel, Melissa L Hill, Reginald Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlying mechanisms responsible for this progression have not been fully characterized. Here, we functionally test the role of metastasis suppressor 1 (MTSS1) in PDAC. Despite evidence showing that MTSS1 could be important for regulating metastasis in many different cancers, its function in PDAC has not been studied. Here, we show that loss of MTSS1 leads to increased invasion and migration in PDAC cell lines. Moreover, PDAC cells treated with cancer-associated fibroblast-conditioned media also have increased metastatic potential, which is augmented by loss of MTSS1. Finally, overexpression of MTSS1 in PDAC cell lines leads to a loss of migratory potential in vitro and an increase in overall survival in vivo. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion and migration driven by the tumor microenvironment and suggest that therapeutic strategies aimed at increasing MTSS1 levels may effectively slow the development of metastatic lesions, increasing survival of patients with PDAC. Impact Journals LLC 2017-01-27 /pmc/articles/PMC5369978/ /pubmed/28146435 http://dx.doi.org/10.18632/oncotarget.14869 Text en Copyright: © 2017 Zeleniak et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zeleniak, Ann E
Huang, Wei
Brinkman, Mary K
Fishel, Melissa L
Hill, Reginald
Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title_full Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title_fullStr Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title_full_unstemmed Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title_short Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
title_sort loss of mtss1 results in increased metastatic potential in pancreatic cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369978/
https://www.ncbi.nlm.nih.gov/pubmed/28146435
http://dx.doi.org/10.18632/oncotarget.14869
work_keys_str_mv AT zeleniakanne lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer
AT huangwei lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer
AT brinkmanmaryk lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer
AT fishelmelissal lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer
AT hillreginald lossofmtss1resultsinincreasedmetastaticpotentialinpancreaticcancer